Opendata, web and dolomites

TrojanDC SIGNED

TrojanDC

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TrojanDC project word cloud

Explore the words cloud of the TrojanDC project. It provides you a very rough idea of what is the project "TrojanDC" about.

eradicate    genes    injection    oncology    resistance    start    diversity    markets    dendritic    patient    re    seasoned    fastest    combination    roche    sound    immunotherapies    sme    locked    innovative    shown    shifting    delivers    cancer    demand    health    immune    therapy    instrument    viral    commercialization    performing    fits    immunotherapy    company    paradigm    bms    keen    patients    consistently    presenting    transcription    effectiveness    grant    114    anti    robustly    personalized    develops    technologies    team    costing    educates    swedish    effector    approx    14       market    uses    players    antigens    something    trojandc    cells    despite    named    immunogenic    maximizing    tumor    acquisitions    2024    inducing    form    car    proprietary    cell    global    scientists    tumoral    asgard    balanced    gene    founded    merck    overhaul    350k    limited    urgent    data    reprogramming    antigen    price    proof    entrepreneurs    heterogeneous    vector    efficacy    shortcomings    therapeutics    strategy    cagr    lose    critical    size    chances    reliably    vivo   

Project "TrojanDC" data sheet

The following table provides information about the project.

Coordinator
ASGARD THERAPEUTICS AB 

Organization address
address: REVINGEGATAN 19C 1203
city: LUND
postcode: 223 59
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ASGARD THERAPEUTICS AB SE (LUND) coordinator 50˙000.00

Map

 Project objective

Asgard Therapeutics, a Swedish start-up company, was founded based on a unique proprietary in vivo cell reprogramming technology. This paradigm-shifting gene therapy has the unique potential to overhaul the cancer immunotherapy market.

Our gene therapy, named TrojanDC, delivers immune-genes into the tumor and re-educates cancer cells to become anti-tumor immune cells. It uses a viral vector to deliver a unique combination of three critical transcription factors (genes) through intra-tumoral injection. The transcription factors make cancer cells become antigen-presenting dendritic cells. These immunogenic cells present their own diversity of tumor-specific antigens to effector immune cells, reliably and robustly inducing immune responses that eradicate the heterogeneous tumor.

Cancer remains a major health challenge. Currently available immunotherapies show strong effectiveness only in a limited number of patients, and often lose their efficacy as the tumor develops resistance. In addition, immunotherapies come with high price (e.g. CAR-T cell approach costing approx. € 350k/patient). Despite these shortcomings, the global immune-oncology market is one of the fastest growing therapeutics markets (€114.6 B by 2024 with a CAGR of 14.3%). Large players like BMS, Merck and Roche have shown to be keen on acquisitions of high-potential technologies. There is thus an urgent need and high demand for innovative cost-effective immunotherapies consistently effective in a broader range of cancer patients – something that Asgard Therapeutics will deliver with TrojanDC in the form of a personalized and highly specific immune therapy using a ‘one-size-fits-all’ approach.

With in-vivo proof-of-concept data already obtained and a balanced team of high-performing scientists and seasoned entrepreneurs, Asgard Therapeutics has locked up key factors towards maximizing its chances of success. This SME instrument grant will ensure a sound strategy towards commercialization of TrojanDC.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TROJANDC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TROJANDC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Preemie (2019)

Personalised nutrition of low-birth-weight infants

Read More  

Savesight (2020)

Contact lens embedded sensor for ocular hypertension and glaucoma monitoring

Read More  

Proteus 25 (2018)

Developing the world’s first food wrapping machine with organic film

Read More